Loading...
•
Jun 30, 2024
Rigel Q2 2024 Earnings Report
Reported financial results, including record revenues from TAVALISSE and REZLIDHIA, and successful transfer of GAVRETO to the commercial portfolio.
Key Takeaways
Rigel Pharmaceuticals reported total revenues of $36.8 million for the second quarter of 2024, driven by record sales of TAVALISSE and REZLIDHIA, as well as the addition of GAVRETO to their commercial portfolio. The company reported a net loss of $1.0 million, approaching net income break even.
Total revenues were $36.8 million, driven by TAVALISSE, REZLIDHIA, GAVRETO net product sales, and contract revenue from collaborations.
TAVALISSE net product sales grew 24% compared to the same period in 2023.
REZLIDHIA net product sales grew 102% compared to the same period in 2023.
GAVRETO became commercially available from Rigel on June 27, 2024.
Forward Guidance
The company looks to maintain their financial discipline as they expand their commercial reach and advance their development programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...